Cyclerion shares jump 16.14% after-hours on merger with Korsana and $380M financing to advance Alzheimer’s therapy pipeline.

Cyclerion Therapeutics surged 16.14% in after-hours trading following the announcement of a definitive merger agreement with Korsana Biosciences, a private biotechnology company focused on neurodegenerative diseases. The combined entity, to be named Korsana Biosciences, will trade under the ticker “KRSA” and will leverage Korsana’s lead program, KRSA-028, a next-generation antibody targeting Alzheimer’s disease. The merger is supported by a $380 million private financing, expected to fund operations through 2029 and key clinical milestones, enhancing investor optimism about the company’s future pipeline and value creation potential.